API
Active Pharmaceutical Ingredients (API)
At Dr. Ashleys, we specialize in the development, distribution, and supply of both complex and generic Active Pharmaceutical Ingredients (APIs). Our API business is a cornerstone of our pharmaceutical operations, reflecting our unwavering commitment to excellence in the industry. Our state-of-the-art Research and Development center is the heart of our innovation. Here, we focus on developing and optimizing cutting-edge process technologies essential for manufacturing APIs across a wide range of therapeutic categories. We pride ourselves on maintaining a comprehensive impurity portfolio, ensuring a prompt and reliable supply of high-quality APIs. Our deep understanding of the pharmaceutical industry’s stringent quality demands drives us to consistently meet and exceed expectations.

API Market
The API market, reported by Grand View Research, was estimated at $255 Billion in 2024 with market growth trajectory to reach $839 Billion by 2033. As the global population continues to age and the growing prevalence of chronic diseases such as cancer, cardiovascular disease, diabetes as well as acute respiratory and GI infections, the global demand for API’s will continue to grow at a rapid pace.
Although, the North America dominates upwards of 35% of the market, Asia Pacific is experiencing the fastest growth in the API market, supported by rising deposable incomes, increasing urbanization and a growing middle class. Other regions such as Europe will also command a growing share of the API trajectory market of $839 Billion.
Dr. Ashleys is the leader of API’s in Asia Pacific and European markets as well as Latin America and Africa. As soon as our 86,00 SQF Research & Development Center adjacent to our new 156,000 sf state-of-the-art pharmaceutical European manufacturing facility becomes fully operational in 2026, Dr. Ashleys will continue to expand its global leadership role in the manufacturing and distribution of API’s.